Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 458.5 JPY -0.79% Market Closed
Market Cap: 2.9T JPY
Have any thoughts about
Olympus Corp?
Write Note

Olympus Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Olympus Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Olympus Corp
TSE:7733
Income from Continuing Operations
ÂĄ28.3B
CAGR 3-Years
-31%
CAGR 5-Years
-4%
CAGR 10-Years
2%
Terumo Corp
TSE:4543
Income from Continuing Operations
ÂĄ119.5B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
13%
Sysmex Corp
TSE:6869
Income from Continuing Operations
ÂĄ53.5B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
8%
Nihon Kohden Corp
TSE:6849
Income from Continuing Operations
ÂĄ14B
CAGR 3-Years
-14%
CAGR 5-Years
7%
CAGR 10-Years
2%
JEOL Ltd
TSE:6951
Income from Continuing Operations
ÂĄ25.1B
CAGR 3-Years
66%
CAGR 5-Years
34%
CAGR 10-Years
20%
Fukuda Denshi Co Ltd
TSE:6960
Income from Continuing Operations
ÂĄ18.2B
CAGR 3-Years
5%
CAGR 5-Years
14%
CAGR 10-Years
11%
No Stocks Found

Olympus Corp
Glance View

Market Cap
2.9T JPY
Industry
Health Care

Olympus Corp., a global leader in optical and digital precision technology, has carved a remarkable niche in the healthcare and life sciences sectors. Founded in Japan in 1919, the company initially focused on cameras and microscopes but has since evolved into a dominant player in the medical device arena, particularly known for its innovative imaging systems, endoscopy equipment, and surgical solutions. Olympus's commitment to enhancing healthcare outcomes is underscored by its significant investments in research and development, enabling the company to deliver cutting-edge solutions that improve patient care and empower healthcare professionals. With a strong presence in over 40 countries, Olympus not only addresses prevailing healthcare challenges but also actively participates in the global push toward minimally invasive procedures, thereby appealing to a growing segment of health-conscious patients and cost-sensitive healthcare systems. For investors, Olympus Corp. presents an intriguing opportunity characterized by resilient financial performance and strategic growth initiatives. The company has consistently demonstrated robust revenue generation, bolstered by its leadership in the endoscopy market, which accounts for a substantial portion of its sales. Furthermore, Olympus is strategically focused on expanding its product offerings through acquisitions and collaborations, reinforcing its commitment to innovation. The growing demand for minimally invasive surgeries, driven by advances in technology and patient preferences, positions Olympus favorably for future growth. With its solid foundation, continuous evolution, and commitment to sustainability, Olympus Corp. stands as a compelling investment option for those looking to align with a company dedicated to transforming healthcare and enhancing lives.

Intrinsic Value
2 702.13 JPY
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Olympus Corp's Income from Continuing Operations?
Income from Continuing Operations
28.3B JPY

Based on the financial report for Jun 30, 2024, Olympus Corp's Income from Continuing Operations amounts to 28.3B JPY.

What is Olympus Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
2%

Over the last year, the Income from Continuing Operations growth was -77%. The average annual Income from Continuing Operations growth rates for Olympus Corp have been -31% over the past three years , -4% over the past five years , and 2% over the past ten years .

Back to Top